05B4 Mookerjee, Bijoyesh P. - Thomas Jefferson University - Thomas Jefferson University
Dr. Mookerjee

Bijoyesh P. Mookerjee, MD

Contact Dr. Mookerjee

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
  2. Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: A randomized Phase II study
  3. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: A double-blind, randomized phase III study (HORIZON III)
  4. Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study
  5. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing
  6. Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host Disease
  7. Adenovirus DNA polymerase is recognized by human CD8+ T cells
  8. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy
  9. T Cell Repertoire Complexity Is Conserved after LLME Treatment of Donor Lymphocyte Infusions
  10. In vitro methods for generating highly purified EBV associated tumor antigen-specific T cells by using solid phase T cell selection system for immunotherapy
  11. Treatment of Adenovirus Disease in Stem Cell Transplant Recipients with Cidofovir
  12. Cytoprotection in acute myelogenous leukemia (AML) therapy
  13. 05B4
  14. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma
  15. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy
  16. Overcoming drug resistance: Targeting more than one site
  17. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB
  18. Autologous stem cell transplantation (ASCT) followed by consolidation chemotherapy for multiple myeloma (MM)
  19. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia- inducible factor 1α
  20. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus
  21. p53-mediated repression of nuclear factor-κB RelA via the transcriptional integrator p300
0